NCT02581839View on ClinicalTrials.gov

Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 17, 2015

Primary Completion Date

July 2, 2018

Study Completion Date

July 2, 2020

Conditions
Metastatic Breast CancerBrain Metastases
Interventions
DRUG

Eribulin Mesylate

Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.

DEVICE

MRI

An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate

DRUG

Pre-Medication: Zofran

Zofran at 8mg orally. Given at the discretion of the treating physician

DRUG

Pre-Medication: Decadron

decadron at 8mg orally. Given at the discretion of the treating physician

Trial Locations (2)

44106

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

NCT02581839 - Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate | Biotech Hunter | Biotech Hunter